- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria
A panel of experts discuss switching between different antihistimines and other medications when treating CSU patients.
EP: 1.The Pathophysiology of Chronic Spontaneous Urticaria
EP: 2.Hallmark Symptoms of Chronic Spontaneous Urticaria
EP: 3.The Epidemiology Associated With Chronic Spontaneous Urticaria
EP: 4.Differential Diagnosis When Considering Chronic Spontaneous Urticaria
EP: 5.Healthcare Specialties Involved in Managing Patients With Chronic Spontaneous Urticaria
EP: 6.Therapies Typically Used in the Firstline For Patients With Chronic Spontaneous Urticaria
EP: 7.Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria
EP: 8.The Use of Systemic Corticosteroids In Chronic Spontaneous Urticaria Treatment
EP: 9.Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments
EP: 10.Key Updates Needed in Chronic Spontaneous Urticaria Guidelines
EP: 11.The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment
EP: 12.Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment
EP: 13.Patient Education, Provider Education, and Overall Final Thoughts
Video content above is prompted by the following question(s):
- A significant number of patients with CSU do not respond adequately to antihistamines. What is your approach to switching between (or adding on) antihistamines and when do you switch to another class of medications?
- How does antihistamine switching and treatment selection correlate with timing of disease episodes?
- If patients aren’t responding well to antihistamines, which therapies do you use next? When do you consider using biologics? What considerations do you take into account and what ultimately is driving that decision?
Peanut Oral Immunotherapy Extends Relief to Adults, Highlights Need for Future Research
June 3rd 2025Adults with peanut allergy experienced effective treatment with peanut oral immunotherapy but future studies are necessary to confirm and characterize safety profiles among various subgroups.
Read More
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
